Amprenavir (Oral solution)

Propylene Gylcol Excipient: Risk of toxicity from large amount of excipient contraindicates use in children < 4 yrs and in certain other populations and used with caution in others. Consult complete prescribing information. Oral solution should only be used when capsules or other protease inhibitors are not therapeutic options.

Product discontinued: February 2008

Patient Counseling Information

Lexiva

Package Inserts

Amprenavir

Updated June 2009

Disclaimer: This information presents a SUMMARY of Black Box data from product information labeling and does not address additional warnings, precautions, or other important safety data in the product insert. Patient care decisions SHOULD NOT be made without reviewing the most recent product information insert, which may be obtained from the manufacturer. This table may not be complete as it was prepared using product information from package inserts. It is periodically updated with supplemental information from FDA safety alerts, the FDA labeling announcements, and new drug approvals.

Formweb is a product of Formulary Productions, LLC. Visit our website at www.formweb.com for more information on online formularies featuring Black Box Warnings.
901-767-3000